Category: Health

New Delhi, Apr 10 (BNP): World Homoeopathy Day is being observed on April 10, commemorating the birth anniversary of Dr. Samuel Hahnemann, the German physician who founded homoeopathy in the late 18th century. This year’s theme, “Homoeopathy for Sustainable Health,” highlights the growing focus on holistic and long-term wellness through alternative systems of medicine.

Homoeopathy, derived from the Greek words “homoios” (similar) and “pathos” (suffering), is based on the principle of treating illness with highly diluted substances that produce symptoms similar to the disease in healthy individuals. The system was formalised by Hahnemann in 1796 and continues to be guided by his foundational work, Organon of Medicine.

 Pic Credit: https://x.com/PMOIndia

Two core principles define homoeopathy: “like cures like,” which suggests that substances causing symptoms in a healthy person may help treat similar symptoms in a patient; and the “law of minimum dose,” which advocates the use of highly diluted remedies to stimulate the body’s natural healing process while reducing side effects.

Homoeopathic medicines are typically prepared from natural sources such as plants, minerals, and animal products through processes of dilution and succussion. They are administered in various forms, including tablets, globules, and liquid preparations. A key feature of the system is its individualised treatment approach, where therapy is tailored to a patient’s overall physical and mental condition rather than focusing solely on the disease.

India remains one of the largest centres for homoeopathy in the world. According to official data, the country has around 3.45 lakh registered homoeopathy doctors, 8,593 dispensaries, 277 educational institutions, and 34 research centres, reflecting its strong institutional base.

Homoeopathy was introduced in India in 1810, when German missionaries first brought its medicines to the country. Over time, it has become an integral part of India’s pluralistic healthcare system, supported by a growing workforce and expanding public acceptance.

Officials and experts note that the system continues to evolve through research and education, with increasing emphasis on evidence-based practice and integration into broader healthcare goals. The observance of World Homoeopathy Day also serves to promote awareness about its role in preventive care and sustainable health systems.

New Delhi, Apr 9 (BNP): The government has announced that the 2026 edition of Poshan Pakhwada will focus on enhancing brain development in children during the crucial first six years of life.

This initiative aims to raise awareness about nutrition, cognitive stimulation, and overall early childhood development, recognizing that the initial years are critical for lifelong learning, health, and productivity. By emphasizing proper nutrition, responsive caregiving, and early learning, the program seeks to ensure that children reach their full developmental potential.

Officials highlighted that Poshan Pakhwada will involve community outreach, awareness campaigns, and collaboration with health workers, schools, and local organizations to educate parents and caregivers on practices that promote brain growth. Special attention will be given to preventing malnutrition, micronutrient deficiencies, and other factors that can hinder cognitive development.

Experts note that investing in the first six years of life not only strengthens individual outcomes but also contributes to broader societal benefits, including improved education, health, and economic productivity. The initiative is part of India’s ongoing efforts to create a healthier, smarter, and more resilient generation.

Apr 8: For decades, seeking world-class medical care in India often meant traveling to New Delhi — a journey that was not just expensive, but emotionally and physically draining for millions of families. Today, that reality is steadily changing.

Across the country, from smaller cities to remote regions, quality healthcare is becoming more accessible than ever before. What was once concentrated in a few urban hubs is now spreading into a more connected, nationwide system — bringing hope closer to people’s homes.

At the heart of this transformation are the people who make healthcare possible: doctors.

Over the past decade, India has made a significant push to strengthen its medical workforce. The number of MBBS seats has more than doubled — rising from about 50,000 in 2014 to nearly 1.2 lakh today. Postgraduate seats have also seen a sharp increase, growing from around 30,000 to about 80,000.

Behind these numbers lies a larger story — one of opportunity and preparedness. With more medical colleges opening and more students entering the profession, India is building a stronger pipeline of trained healthcare professionals. This means that patients in smaller towns no longer have to depend solely on distant metro cities for specialized care.

For families, this shift is deeply personal. It means fewer long journeys in times of crisis, quicker access to treatment, and the comfort of being cared for closer to home.

India’s healthcare journey is far from complete, but the direction is clear: a future where quality medical care is not defined by geography, but guaranteed as a right — wherever you live.

All India Institute of Medical Sciences Delhi has introduced a state-of-the-art virtual reality (VR) training centre aimed at enhancing medical education and clinical training for students.

The new facility uses immersive VR technology to simulate real-life medical scenarios, allowing students to practice procedures and decision-making in a controlled, risk-free environment. This approach is expected to strengthen practical skills and improve confidence before handling actual patients.

According to institute officials, the initiative is part of a broader effort to integrate advanced technology into medical training and keep pace with global standards in healthcare education. The VR centre will support learning across multiple disciplines, offering interactive modules tailored to various medical specialties.

The launch marks a significant step toward modernizing medical education in India, providing students with innovative tools to gain hands-on experience and improve patient care outcomes.

Chennai, Apr 06: Shri M. Venkaiah Naidu, former Vice President of India, is set to inaugurate the 10th edition of CAHOCON 2026, India’s premier healthcare quality conference organized by the Consortium of Accredited Healthcare Organizations (CAHO), scheduled to be held in Chennai from April 10 to 12, 2026.

Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, will be the Guest of Honour at the inaugural session. Dr. C. Sylendra Babu, IPS (Retd.), former Director General of Police and Head of Police Force, Tamil Nadu, will be the Guest of Honour at the Graduation Ceremony. The event is expected to bring together around 2,500 healthcare leaders, clinicians, administrators, and policymakers, including over 200 international delegates, to deliberate on advancements in patient safety, healthcare quality, accreditation, and digital transformation. Ms. Mallika Srinivasan, Chairman & MD, TAFE will be the Chief Guest and Mr. Sunil Kumar Barnwal IAS, Additional Secretary and CEO, National Health Authority, Government of India will be the Guest of Honour at the valedictory ceremony.

Other dignitaries participating in CAHOCON 2026 include Dr. Vijay Agarwal, President; Dr. Lallu Joseph, Secretary General, Consortium of Accredited Healthcare Organizations, and AGS & Quality Manager at Christian Medical College Vellore; Dr. Nalla G Palaniswami, Organizing Chairperson CAHOCON 2026, and Chairman of Kovai Medical Centre and Hospital; Dr. S. Manivannan, Organizing Co-Chairperson, and Founder & Managing Director of Kauvery Group of Hospitals; Dr. Sathish Devadoss, Organizing Secretary, and Vice Chairman of Devadoss Multispecialty Hospitals; and Dr. Ilankumaran Kaliamoorthy, Academic Committee Member, CAHOCON 2026, and CEO of Apollo Hospitals Chennai.

Guided by the theme ‘Tech, Touch, Trust- The new Healthcare code.’, CAHOCON 2026 will emphasize the human connection, reliability, and innovation at the heart of advancing healthcare quality and patient safety. The main conference will feature high-impact scientific sessions, panel discussions, innovation showcases, and interactive networking opportunities, along with poster presentations by researchers and clinicians that highlight innovative projects and foster knowledge exchange.

Alongside the conference, CAHOCON 2026 will host a comprehensive healthcare exhibition with over 200 stalls, showcasing cutting-edge products and services from leading medical equipment manufacturers, digital health companies, pharmaceutical firms, and service providers. The conference will also feature four breakout houses, designed to facilitate smaller group discussions, interactive workshops, and focused learning sessions.

Recognized by the International Society for Quality in Health Care (ISQua) as the first ISQua Regional Conference for South Asia, CAHOCON 2026 will witness addresses by 20 ISQua experts. The conference will honour excellence in healthcare quality and patient safety through the prestigious CAHO Awards, celebrating institutions and professionals who have made outstanding contributions to advancing healthcare standards.

A key highlight of CAHOCON 2026 is the pre-conference workshops. Over 40 such workshops will be organized on April 10 engaging 32 leading hospitals from Chennai, providing hands-on training and practical insights into quality improvement and patient safety for the participants.

Over the past decade, CAHO has evolved into a powerful national movement dedicated to strengthening healthcare quality and patient safety across India. Through continuous training, accreditation support, knowledge-sharing platforms and collaborative initiatives, the organization is working to build a culture where quality and safety are embedded in every aspect of healthcare delivery.

CAHOCON is one of the most influential platforms for advancing healthcare quality and patient safety in India. This collaborative forum aims to strengthen a culture of continuous improvement in healthcare systems and ensure that patients across the country benefit from safer and higher-quality care.

New Delhi: The Jan Vishwas Bill is expected to bring significant relief to India’s healthcare ecosystem by reducing regulatory pressure and encouraging smoother operations across the sector, according to the Ministry.

The Bill focuses on decriminalising minor offences and replacing them with civil penalties, a move that could greatly benefit hospitals, diagnostic centres, pharmaceutical firms, and medical device companies. Instead of facing criminal action for procedural lapses, healthcare providers will now be subject to warnings, improvement notices, or monetary penalties—making compliance less intimidating and more practical.

Pic Credit: Pexel

For the health sector, this shift is particularly important. Medical institutions often deal with complex regulations, and even small documentation errors could earlier lead to severe legal consequences. By removing the fear of criminal prosecution for such minor issues, the Bill allows healthcare professionals to focus more on patient care rather than legal risks.

The reform is also expected to boost investment and innovation. A more predictable and business-friendly regulatory environment can attract new players in areas like pharmaceuticals, medical technology, and health services. This could improve infrastructure, expand access to care, and support the growth of India’s healthcare industry.

Additionally, faster and more transparent compliance processes may improve service delivery. With fewer legal hurdles, approvals and operations can become more efficient, ultimately benefiting patients through better access and reduced delays.

Officials believe that the Bill will not only enhance ease of doing business but also strengthen the overall healthcare system by making it more responsive, efficient, and growth-oriented.

SAN FRANCISCO, CA – Apr 1 – Canopy, the category leader in connected safety platforms for U.S. health systems, announced that it now protects more than 350,000 lives nationwide and has expanded itsClinical Strategy Team to further the shift from reactive incident response to proactive, pre-escalation prevention with rich clinical focus and experience.

As workplace violence, nurse burnout, and staff turnover continue to strain hospital margins, Canopy is investing in deep clinical expertise to provide health systems with the strategies and tools needed for safer daily operations. The expansion includes the addition of Dr. Ryan Oglesby, PhD, MHA, RN, CEN, CFRN, NEA-BC, 2025 National Emergency Nurses Association (ENA) and this year’s Past President, as a Clinical Strategy Director. He joins current Clinical Strategy Director Jeanne Venella, DNP, MS, CEN, CPEN, a nationally recognized expert in clinical operations and patient safety. Together, they strengthen Canopy’s ability to partner directly with executive and nurse leaders on large-scale safety initiatives.

“At Canopy, we’re turning the commitment to nurse safety into real-world, real-time activation so that bedside caregivers can get help the moment they need it,” said Ryan Oglesby, Clinical Strategy Director. “By growing this clinical strategy team, we are bridging the gap between frontline caregivers and hospital leadership to ensure the protections necessary to keep clinicians focused on taking care of patients.”

The company’s rapid growth, fueled by its expanding team and recent Series B funding, reflects rising demand from health system leaders who recognize that safety is a critical driver of patient outcomes. Workplace violence drives turnover, increases labor costs, and disrupts productivity. To address these challenges, Canopy is accelerating the evolution of its Connected Safety Platform.

Over the past six months, Canopy has introduced enhanced mobile responder capabilities across Android and iOS, as well as integrations with Epic, Vocera, and TigerConnect, providing security and clinical teams with immediate, high-fidelity location data. Coupled with advanced reporting and real-time analytics, these updates empower leadership to identify high-risk areas and optimize response protocols.

In their recent Healthcare Safety Report, which surveyed over 1,000 healthcare workers and leaders, Canopy found that nearly 85% of respondents have experienced at least one workplace violence event in their careers. The report also highlighted a direct link to turnover, with over one-third of workers considering leaving their positions due to safety issues.

“Our mission is to safeguard healthcare workers wherever they occur across the campus—from the parking garage to the exam room,” said Jeanne Venella, Clinical Strategy Director. “As hospitals move beyond simply reacting to incidents, we are providing the infrastructure for a prevention-first model that strengthens both staff well-being and overall operations.” At the last ENA conference I attended, a nurse approached me in our exhibit hall and stated, “My Canopy button saved my life last week!” Emergency Department Nurse at TJU.

Canopy’s platform is actively trusted by leading organizations, including the University of Michigan Health-Sparrow and ECU Health. The company will continue expanding its Clinical Strategy Team as part of its long-term commitment to helping health systems protect their people and performance.

“We knew we couldn’t eliminate workplace violence entirely, but we could certainly prevent the harm coming to our team members. We wanted them to feel empowered, not monitored. Once we rolled [Canopy’s platform] out, you could feel the shift—they finally felt safer.” Chris Nemets, Regional CNIO, University of Michigan Health, states about incorporating Canopy into Michigan Health’s system.

Pic Credit: Pexel

India’s bioeconomy is fast emerging as one of the country’s most dynamic growth engines, steadily approaching the $200 billion mark. Fueled by innovation, research, and a thriving startup ecosystem, the sector is redefining how science contributes to economic progress and everyday life.

From Niche to Mainstream

Once limited to specialized research and pharmaceuticals, the bioeconomy has expanded into a wide spectrum of industries, including healthcare, agriculture, biofuels, and environmental solutions. This transformation reflects India’s ability to combine scientific expertise with real-world applications, creating solutions that are both scalable and impactful.

Innovation Driving the Momentum

At the heart of this growth lies a strong push for innovation. Startups, research institutions, and established companies are working together to develop next-generation technologies in areas such as biotechnology, genomics, and sustainable agriculture.

Supportive government policies and increased funding have further accelerated this momentum, enabling new ideas to move from laboratories to markets more quickly than ever before.

Beyond Growth: A Broader Impact

The rise of the bioeconomy is not just an economic story—it is also about addressing critical challenges. From improving healthcare access to developing climate-resilient crops and clean energy alternatives, the sector is playing a key role in shaping a more sustainable future.

It is also creating skilled jobs, attracting global investments, and strengthening India’s position as a hub for affordable and innovative solutions.

Looking Ahead

As the bioeconomy edges closer to the $200 billion milestone, the focus is shifting toward scaling innovation and deepening collaboration between industry and academia. Strengthening infrastructure and nurturing talent will be crucial to sustaining this growth.

With strong foundations and growing global relevance, India’s bioeconomy is entering a new phase—one defined by innovation, resilience, and the potential to make a lasting impact on both the economy and society.

Baltimore, USA, Apr 03: Researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have developed a novel intranasal DNA vaccine that could significantly improve treatment outcomes for tuberculosis (TB), one of the world’s deadliest infectious diseases. The findings were published in the Journal of Clinical Investigation.

The innovative vaccine is designed to be administered through the nose and works alongside standard drug therapies to enhance the body’s immune response against TB. It specifically targets drug-tolerant bacterial “persisters,” which are known to survive prolonged antibiotic treatment and contribute to disease relapse.

According to the World Health Organization, TB remains a global health crisis, with approximately 2 billion people carrying latent infections and more than 10 million new active cases reported annually. In 2024 alone, the disease caused an estimated 1.2 million deaths, making it the leading cause of death from a single infectious agent.

“Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster, reduced lung inflammation, and prevented relapse after treatment ended,” said Styliani Karanika, M.D., lead author of the study and faculty member at the Johns Hopkins Center for Tuberculosis Research.

The vaccine combines two genes—relMtb and Mip3α—to stimulate a targeted immune response. This fusion helps attract and activate dendritic cells, which play a crucial role in presenting TB-related proteins to T cells, thereby enabling a more effective immune attack on the bacteria.

Unlike traditional vaccines, the intranasal delivery method focuses the immune response directly in the lungs—the primary site of TB infection. This approach not only enhances localized immunity but also generates long-lasting systemic immune responses.

Preclinical studies demonstrated promising results. In mice, the vaccine improved bacterial clearance, reduced inflammation, and prevented relapse. Additionally, it enhanced the effectiveness of a powerful TB drug combination, suggesting potential benefits in treating drug-resistant TB cases.

Further testing in rhesus macaques showed that the vaccine generated durable immune responses in both the bloodstream and respiratory tract, lasting at least six months. While these findings are encouraging, researchers emphasized that additional studies are needed before progressing to human clinical trials.

“Our nonhuman primate data provide an important translational bridge between animal studies and future clinical applications,” added Karanika. “This approach could help shorten treatment durations and improve outcomes, particularly in difficult-to-treat TB cases.”

The study highlights a broader shift in TB treatment strategies, focusing on combining immunotherapy with antibiotics to target both active and persistent bacteria. Researchers note that DNA vaccines also offer practical advantages, including stability and efficient manufacturing, which could support large-scale deployment if proven effective in humans.

The research was supported by multiple funding sources, including grants from the National Institutes of Health, and represents a significant step forward in the global fight against tuberculosis.